Two trials in the wake of the paclitaxel-coated products controversy

The BEST-CLI trial in the USA is set to continue, while the SWEDEPAD trials from (and BASIL-3 in the UK) have paused enrolment in light of the data from Katsanos et al meta-analysis that was published in JAHA in 2018. Vascular News spoke to Matthew Menard (Boston, USA) and Mårten Falkenberg (Gothenburg, Sweden), principal investigators of the respective trials, at VLF 2019 to understand the two different trajectories of these trials. The investigators emphasise that determining the correct response to these trials is an ongoing process as new information comes to light.

Menard, Matthew and Falkenberg, Mårten

Add comment

Editor’s Peripheral Pick

    Subscribeto receive the very best in medical videos